ATE89315T1 - Faktor viii-analog, verfahren zu dessen herstellung und dieses enthaltende zusammensetzung. - Google Patents

Faktor viii-analog, verfahren zu dessen herstellung und dieses enthaltende zusammensetzung.

Info

Publication number
ATE89315T1
ATE89315T1 AT88402078T AT88402078T ATE89315T1 AT E89315 T1 ATE89315 T1 AT E89315T1 AT 88402078 T AT88402078 T AT 88402078T AT 88402078 T AT88402078 T AT 88402078T AT E89315 T1 ATE89315 T1 AT E89315T1
Authority
AT
Austria
Prior art keywords
factor viii
analogue
production
composition containing
deleted
Prior art date
Application number
AT88402078T
Other languages
English (en)
Inventor
Pierre Meulien
Andrea Pavirani
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9354094&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE89315(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Transgene Sa filed Critical Transgene Sa
Application granted granted Critical
Publication of ATE89315T1 publication Critical patent/ATE89315T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT88402078T 1987-08-11 1988-08-10 Faktor viii-analog, verfahren zu dessen herstellung und dieses enthaltende zusammensetzung. ATE89315T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8711415A FR2619314B1 (fr) 1987-08-11 1987-08-11 Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
EP88402078A EP0303540B1 (de) 1987-08-11 1988-08-10 Faktor VIII-Analog, Verfahren zu dessen Herstellung und dieses enthaltende Zusammensetzung

Publications (1)

Publication Number Publication Date
ATE89315T1 true ATE89315T1 (de) 1993-05-15

Family

ID=9354094

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88402078T ATE89315T1 (de) 1987-08-11 1988-08-10 Faktor viii-analog, verfahren zu dessen herstellung und dieses enthaltende zusammensetzung.

Country Status (8)

Country Link
US (1) US5112950A (de)
EP (1) EP0303540B1 (de)
JP (1) JP2694280B2 (de)
AT (1) ATE89315T1 (de)
CA (1) CA1341169C (de)
DE (1) DE3880922T2 (de)
ES (1) ES2054842T3 (de)
FR (1) FR2619314B1 (de)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5422260A (en) * 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
IE69026B1 (en) 1987-06-12 1996-08-07 Immuno Ag Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
SE465222C5 (sv) * 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
FI923347A0 (fi) * 1990-01-26 1992-07-23 Immuno Ag Blodfaktorer producerade med rekombinant-dna-teknik och foerfarande foer expression av naemnda blodfaktorer samt i naemnda foerfarande anvaenda rekombinanta kokoppvirus.
FR2657884B1 (fr) * 1990-02-05 1994-09-02 Tm Innovation Procede pour la preparation du facteur viii humain et d'analogues du facteur viii.
US5997864A (en) 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
US5833982A (en) * 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5661008A (en) * 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
ATE181108T1 (de) * 1991-08-26 1999-06-15 Immuno Ag Direkt molekuläre klonierung eines modifizierten genoms eines chordopocken-virus
DK53792D0 (da) * 1992-04-24 1992-04-24 Novo Nordisk As Fremgangsmaade til fremstilling af proteiner
AU5462694A (en) * 1992-11-17 1994-06-08 Novo Nordisk A/S Improved recombinant production of proteins having factor viii:c activity
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
DE4437544A1 (de) * 1994-10-20 1996-04-25 Behringwerke Ag Einsatz von vWF-enthaltenden Konzentraten als Kombinationstherapie bei Therapie mit Antithrombotika und Fibrinolytika
US6200560B1 (en) * 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US6221349B1 (en) 1998-10-20 2001-04-24 Avigen, Inc. Adeno-associated vectors for expression of factor VIII by target cells
EP1038959A1 (de) 1999-03-17 2000-09-27 Aventis Behring Gesellschaft mit beschränkter Haftung Faktor VIII ohne B-Domän, der ein oder mehrere Insertionsstücke von verkürztem Intron I des Faktors IX enthält
US20040023292A1 (en) * 2001-10-19 2004-02-05 Mcswiggen James Method and reagent for the detection of proteins and peptides
EP1233064A1 (de) 2001-02-09 2002-08-21 Aventis Behring Gesellschaft mit beschränkter Haftung Modifizierte Faktor VIII cDNA und deren Verwendung bei der Produktion von Faktor VIII
EP1284290A1 (de) * 2001-08-08 2003-02-19 Aventis Behring GmbH Erhöhung der Expression von Faktor VIII durch Insertion von spleissbaren Nukleotidsequenzen in Faktor VIII cDNA
EP1424344A1 (de) * 2002-11-29 2004-06-02 Aventis Behring Gesellschaft mit beschränkter Haftung Modifizierte cDNA des Factors VIII und Derivate davon
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
EP1668143B1 (de) 2003-09-30 2013-03-20 The Trustees of The University of Pennsylvania Claden und sequenzen von adeno-assoziiertem virus (aav), diese enthaltende vektoren sowie verwendungen dafür
JP2008512098A (ja) * 2004-09-07 2008-04-24 アーケミックス コーポレイション フォン・ビルブラント因子に対するアプタマー、および血栓性疾患の処置剤としてのその使用
AU2005282380A1 (en) * 2004-09-07 2006-03-16 Archemix Corp. Aptamer medicinal chemistry
US7566701B2 (en) * 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
EP1707634A1 (de) 2005-03-29 2006-10-04 Octapharma AG Verfahren zur Isolierung von rekombinant hergestellten Proteinen
DE23193606T1 (de) 2005-04-07 2024-02-15 The Trustees Of The University Of Pennsylvania Verfahren zur erhöhung der funktion eines aav-vektors
EP1739179A1 (de) 2005-06-30 2007-01-03 Octapharma AG Serumfreie stabile Transfektion und Produktion von rekombinanten humanen Proteinen in humanen Zelllinien
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
CA2679107C (en) * 2007-02-23 2018-01-16 Sk Chemicals Co., Ltd. Process for producing and purifying factor viii and its derivatives
WO2008150495A2 (en) * 2007-06-01 2008-12-11 Archemix Corp. Vwf aptamer formulations and methods for use
DK3178835T3 (da) 2009-02-03 2019-06-24 Amunix Pharmaceuticals Inc Forlængede rekombinante polypeptider og sammensætninger omfattende samme
CA2771999A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
EP4382170A3 (de) 2009-12-06 2024-09-04 Bioverativ Therapeutics Inc. Chimäre und hybride faktor-viii-fc-polypeptide und verfahren zur verwendung davon
WO2011095604A1 (en) 2010-02-04 2011-08-11 Octapharma Biopharmaceuticals Gmbh Half-life prolongation of proteins
WO2011126808A2 (en) 2010-03-29 2011-10-13 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
US9315825B2 (en) 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
PT2591006T (pt) 2010-07-09 2019-07-29 Bioverativ Therapeutics Inc Moléculas de cadeia simples processáveis e polipéptidos preparados utilizando as mesmas
US9611310B2 (en) 2010-07-09 2017-04-04 Bioverativ Therapeutics Inc. Systems for factor VIII processing and methods thereof
CN103502458B (zh) 2011-02-17 2016-11-16 宾夕法尼亚大学托管会 用于改变组织特异性和改善aav9-介导的基因转移的组合物和方法
CA2838833A1 (en) 2011-06-10 2012-12-13 Biogen Idec Ma Inc. Pro-coagulant compounds and methods of use thereof
EP4169525A1 (de) 2011-07-08 2023-04-26 Bioverativ Therapeutics Inc. Chimäre und hybride faktor-viii-polypeptide und verfahren zur verwendung davon
EA028914B1 (ru) 2011-07-25 2018-01-31 Байоджен Хемофилия Инк. Исследования для мониторинга нарушений свертываемости крови
CN103917554B (zh) 2011-10-18 2017-03-08 杰特有限公司 用于改善重构后纯化的因子viii的稳定性的方法
HRP20191920T1 (hr) 2012-01-12 2020-01-10 Bioverativ Therapeutics Inc. Kimerni polipeptidi faktora viii i njihova uporaba
EA038705B1 (ru) 2012-01-12 2021-10-07 Биовератив Терапьютикс Инк. Способы снижения иммуногенности фактора свёртывания крови viii у пациентов, получающих лечение фактором viii
WO2013123457A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
CN111548418A (zh) 2012-02-15 2020-08-18 比奥贝拉蒂治疗公司 因子viii组合物及其制备和使用方法
AU2013270682A1 (en) 2012-06-08 2014-12-11 Biogen Ma Inc. Procoagulant compounds
AU2013270683A1 (en) 2012-06-08 2014-12-11 Biogen Ma Inc. Chimeric clotting factors
US10023628B2 (en) 2012-07-06 2018-07-17 Bioverativ Therapeutics Inc. Cell line expressing single chain factor VIII polypeptides and uses thereof
ES2770501T3 (es) 2012-07-11 2020-07-01 Bioverativ Therapeutics Inc Complejo del factor VIII con XTEN y proteína del factor de Von Willebrand y sus usos
WO2014018777A2 (en) 2012-07-25 2014-01-30 Biogen Idec Ma Inc. Blood factor monitoring assay and uses thereof
AU2013331000B2 (en) 2012-10-18 2018-04-19 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
WO2014070953A1 (en) 2012-10-30 2014-05-08 Biogen Idec Ma Inc. Methods of Using FVIII Polypeptide
RS61387B2 (sr) 2013-02-15 2024-06-28 Bioverativ Therapeutics Inc Gen optimizovanog faktora viii
SG11201505926VA (en) 2013-03-15 2015-09-29 Biogen Ma Inc Factor ix polypeptide formulations
ES2926798T3 (es) 2013-03-15 2022-10-28 Bioverativ Therapeutics Inc Formulaciones de polipéptido de factor VIII
US9719106B2 (en) 2013-04-29 2017-08-01 The Trustees Of The University Of Pennsylvania Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
KR20230007555A (ko) 2013-06-28 2023-01-12 바이오버라티브 테라퓨틱스 인크. Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도
EP3875106A1 (de) 2013-08-08 2021-09-08 Bioverativ Therapeutics Inc. Reinigung von chimären fviii-molekülen
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
WO2015070014A1 (en) 2013-11-08 2015-05-14 Biogen Idec Ma Inc. Procoagulant fusion compound
US10325687B2 (en) 2013-12-06 2019-06-18 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
EA201691111A1 (ru) 2014-01-10 2017-01-30 Байоджен Ма Инк. Химерные белки фактора viii и их применение
WO2015107222A1 (en) 2014-01-20 2015-07-23 Octapharma Ag A process for manufacturing factor viii having an improved ratio of fviii:c/fviii:ag
NZ722391A (en) 2014-02-04 2022-12-23 Biogen Ma Inc Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
CN115094062A (zh) 2015-04-16 2022-09-23 埃默里大学 用于肝脏中蛋白质表达的重组启动子和载体及其用途
UA126016C2 (uk) 2015-08-03 2022-08-03 Біовератів Терапеутікс Інк. Злитий білок фактора іх
CN108884145B (zh) 2015-11-13 2023-08-22 武田药品工业株式会社 用于血友病a的基因治疗的具有增加的表达的编码重组fviii变体的病毒载体
KR102404550B1 (ko) 2015-11-13 2022-05-31 다케다 야쿠힌 고교 가부시키가이샤 A형 혈우병의 유전자 요법을 위한 증가된 발현을 갖는 재조합 fviii 변이체를 인코딩하는 바이러스 벡터
KR20180118659A (ko) 2016-02-01 2018-10-31 바이오버라티브 테라퓨틱스 인크. 최적화된 viii 인자 유전자
JP6877469B2 (ja) 2016-06-24 2021-05-26 モガム・インスティテュート・フォー・バイオメディカル・リサーチＭｏｇａｍ Ｉｎｓｔｉｔｕｔｅ Ｆｏｒ Ｂｉｏｍｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ Ｆｖｉｉｉおよびｖｗｆ因子を含むキメラタンパク質、ならびにそれらの使用
CA3044838A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
KR20190090827A (ko) 2016-12-02 2019-08-02 바이오버라티브 테라퓨틱스 인크. 키메라 응고 인자를 사용해 혈우병성 관절증을 치료하는 방법
MX2020001593A (es) 2017-08-09 2020-07-13 Bioverativ Therapeutics Inc Moleculas de acido nucleico y usos de las mismas.
EP3706720B1 (de) 2017-11-07 2026-07-01 Rani Therapeutics, LLC Gerinnungsfaktorpräparate zur verabreichung in gewebe des darmtraktes unter verwendung einer schluckbaren arzneimittelabgabevorrichtung
US20210038744A1 (en) 2018-02-01 2021-02-11 Bioverativ Therapeutics Inc. Use of lentiviral vectors expressing factor viii
CN112203646A (zh) 2018-04-04 2021-01-08 西吉隆医疗股份有限公司 可植入颗粒和相关方法
KR102914074B1 (ko) 2018-05-18 2026-01-16 바이오버라티브 테라퓨틱스 인크. A형 혈우병의 치료 방법
US12091675B2 (en) 2018-07-16 2024-09-17 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant FVIII variants with increased expression
JP7602454B2 (ja) 2018-08-09 2024-12-18 バイオベラティブ セラピューティクス インコーポレイテッド 核酸分子及び非ウイルス遺伝子治療のためのそれらの使用
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
TWI851647B (zh) 2019-01-16 2024-08-11 日商武田藥品工業股份有限公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
MX2021013310A (es) 2019-05-03 2022-02-11 Rani Therapeutics Llc Preparaciones de factor de cogulación para la administración en el tejido del tracto intestinal usando un dispositivo de administración de medicamentos ingeribles.
AU2020298233A1 (en) 2019-06-19 2022-01-20 Bioverativ Therapeutics Inc. Recombinant factor VIII-Fc for treating hemophilia and low bone mineral density
JP7803014B2 (ja) 2019-09-30 2026-01-21 バイオベラティブ セラピューティクス インコーポレイテッド レンチウイルスベクター製剤
CN114981299A (zh) 2019-12-12 2022-08-30 武田药品工业株式会社 使用编码具有增加的表达的重组fviii变体的病毒载体的a型血友病的基因疗法
JP2023537565A (ja) 2020-06-24 2023-09-04 バイオベラティブ セラピューティクス インコーポレイテッド タンパク質を発現するように改変されたレンチウイルスベクターの調製物から遊離第ｖｉｉｉ因子を除去する方法
CN116209430A (zh) 2020-08-07 2023-06-02 阿米库斯治疗学公司 囊泡靶向蛋白及其用途
EP4355768A1 (de) 2021-06-14 2024-04-24 Takeda Pharmaceutical Company Limited Gentherapie von hämophilie a unter verwendung von für rekombinante fviii-varianten codierenden viralen vektoren mit erhöhter expression
US20230084036A1 (en) 2021-08-23 2023-03-16 Bioverativ Therapeutics Inc. Optimized factor viii genes
KR20240067122A (ko) 2021-09-30 2024-05-16 바이오버라티브 테라퓨틱스 인크. 감소된 면역원성을 갖는 인자 viii 폴리펩타이드를 암호화하는 핵산
WO2024081309A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease
WO2025008774A1 (en) 2023-07-05 2025-01-09 Takeda Pharmaceutical Company Limited Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9203440A (es) * 1985-04-12 1992-07-01 Genetics Inst Proteinas procoagulantes novedosas.
KR910006424B1 (ko) * 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
US5451521A (en) * 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
IL83192A (en) * 1986-07-18 1992-11-15 Gist Brocades Nv Method for the preparation of proteins with factor viii activity by microbial host cells;expression vectors,host cells,antibodies
IL84168A0 (en) * 1986-10-15 1988-03-31 Rorer Int Overseas Human factor viii-c analogs,process for the preparation thereof and pharmaceutical compositions containing the same

Also Published As

Publication number Publication date
US5112950A (en) 1992-05-12
DE3880922D1 (de) 1993-06-17
DE3880922T2 (de) 1993-08-26
ES2054842T3 (es) 1994-08-16
FR2619314A1 (fr) 1989-02-17
JPS6479124A (en) 1989-03-24
CA1341169C (fr) 2001-01-16
JP2694280B2 (ja) 1997-12-24
EP0303540B1 (de) 1993-05-12
FR2619314B1 (fr) 1990-06-15
EP0303540A1 (de) 1989-02-15

Similar Documents

Publication Publication Date Title
DE3880922D1 (de) Faktor viii-analog, verfahren zu dessen herstellung und dieses enthaltende zusammensetzung.
HUT56379A (en) Process for producing a-norsteroid-3-carboxylic acid derivatives and compositions comprising such compounds
ATE82495T1 (de) Verfahren zur herstellung pharmazeutischer mischungen.
EP0122798A3 (en) Rcrf and analogs
DE69133509D1 (de) Verfahren zur herstellung von beta-lactamen
DE69221745D1 (de) Verfahren zur kombinierten Herstellung von organischen Zusammenstellungen und Energie
DE58907083D1 (de) Verfahren zur Herstellung von Benztriazolderivaten.
DE3568048D1 (en) Process for the synthesis of peptides
HUT53664A (en) Process for producing enzyme inhibiting amino acid derivatives and pharmaceutical compositions comprising such compounds as active ingredient
ES483661A1 (es) Procedimiento para la obtencion de derivados de 1,4-dihidro-piridina sila-sustituidos
ES8301090A1 (es) Metodo de preparar agentes para la modificacion artificial de las precipitaciones atmosfericas.
ATE49185T1 (de) Verfahren zur herstellung von halogen-magnesium- alanat und dessen verwendung.
HUT49122A (en) Process for producing pharmaceutical compositions containing pyridyl-ethanol-amine as active component and the active component
DE68926922D1 (de) Verfahren zur Herstellung von L-alpha-Aminosäuren
HUT47374A (en) Fungicide compositions containing /2-cyano-2-oximino-acetyl/-aminoacid derivatives as active components and process for producing the active components
JPS5795950A (en) Novel hexapeptide, manufacture, use as drug and composition
ATE15050T1 (de) Verfahren zur herstellung von cholesterinderivaten und zwischenprodukte dafuer.
ATE25708T1 (de) Biologisch aktive konjugate, ihre herstellung und ihre anwendung.
ATE2144T1 (de) Verfahren zur herstellung von carbazolen und zwischenprodukte dafuer.
PT86228A (de) Verfahren zur herstellung von 6alpha,9alpha-difluor-11beta,17alpha-dihydroxy-16alpha-methil-4-pregnen-3,20-dion und dessen derivate
DE2965364D1 (en) Alpha-difluoromethyl amino acids and pharmaceutical composition containing the same
DK87090A (da) Vasotocin-derivater og farmaceutiske midler indeholdende saadanne derivater
ATE81013T1 (de) Verfahren zur herstellung von faktor viii:cmangelplasma und ein so erhaltenes mangelplasma.
ATE104313T1 (de) Neue 9-g(a)-hydroxy-3-oxo-4,24(25)-stigmastadien26-s|urederivate,verfahren zur herstellung und heilmittel daraus.
FR2559157B1 (fr) Nouvel hexapeptide, son procede d'obtention et les compositions pharmaceutiques qui le contiennent

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee